Skip to the content

What's happening in the world of infectious disease?Viracor presents our IDWeek posters, along with posters from hospitals and healthcare programs utilizing Viracor's ID testing to help diagnose and treat patients.

Not familiar with Viracor? The hospitals we work with turn to us for:

SPEED. Most ID tests result within 8-12 hours of specimen receipt

QUALITY. Dual gene targets reduce false negatives and under quantification

SERVICE. Approximately 60% of transplant programs turn to us for their most critical patient testing and we accept a variety of validated specimen types to give healthcare providers more options

Viracor's IDWeek 2018 Posters


Invasive Mucormycosis Management: Mucorales PCR Provides Important, Novel Diagnostic Information

In immunocompromised patients, high mortality and morbidity of invasive mucormycosis (IM) remain significant healthcare issues due in part to confusion of IM with invasive aspergillosis (IA) and failure to initiate appropriate therapy. A validated Mucorales (MUC) PCR detects the causative agents of IM with good sensitivity and specificity, as reported previously (M-227, ICAAC 2013). Published studies have not definitively determined the frequency of patients for whom pulmonary IA is suspected but IM is present. We aimed to (1) estimate the frequency of MUC PCR positivity in bronchoalveolar lavage (BAL) samples submitted for Aspergillus (ASP) PCR panel testing.




Addressing pulmonary nocardiosis risk in immunocompromised patients: Development and validation of a commercially available PCR

Pulmonary nocardiosis is an infection targeting immunocompromised patients characterized by high mortality and requires non-frontline antibiotics for treatment. Nocardiosis is currently confirmed or excluded by BAL fluid culture followed by further phenotypic identification steps. A culture-independent method with more timely results would accelerate the administration of appropriate treatment. A rapid Nocardia (NOC) PCR assay for BAL has neither been previously validated nor offered for clinical testing to our knowledge.



Letermovir Resistance

Development of a Sequencing Based Assay for Detection of CMV Antiviral Resistance Mutations to Letermovir in UL56

Antiviral resistance to human cytomegalovirus (CMV) is a growing concern for immunocompromised patients on prolonged antiviral regimens, and CMV remains the most clinically significant infection following allogeneic hematopoietic-cell transplantation. Letermovir targets subunit 2 of the viral terminase complex (UL56) and is approved for CMV prophylaxis in adult stem cell transplant recipients. Resistance to letermovir is conferred by point mutations in the UL56 gene, and with the potential clinical need for antiviral resistance testing, we have developed a UL56 sequencing assay covering 23 identified resistance mutations. Here we summarize the performance characteristics of the UL56 antiviral resistance assay.



See how these hospitals and healthcare programs are utilizing Viracor's testing in their posters at IDWeek

CMV T Cell Immunity

Using a commercially available assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by intracellular cytokine staining to predict clinically significant CMV events

Cytomegalovirus (CMV) infection is a common opportunistic infection associated with significant morbidity, mortality, and risk of allograft loss. Early detection of viremia and initiation of treatment prior to disease progression is paramount. Alternatively, in the absence of treatment, many patients also control CMV infection, including low-level viremia, without progressing to disease. Thus, many treatment decisions (e.g. viremia thresholds to initiate treatment) are not currently well-defined. Given the excessive toxicities and costs of antiviral therapy, there is growing interest in assays that measure CMV-specific T-cell immunity (TCI), which may predict protection against infection. The Viracor ® CMV T-cell Immunity Panel (CMV-TCIP) uses flow cytometry and intracellular cytokine staining (ICS) to measure % of CMV-specific CD4+ and CD8+ T-cells. Other currently available TCI commercial assays measure only aggregate (CD4+ and CD8+) or CD8+ immune responses only.




Want to know more about Viracor's CMV Test menu? CLICK HERE


Utility of Serum Beta-D Glucan Assay for Diagnosis of Invasive Fungal Infections in Solid Organ Transplant Recipients

Utility of Serum Beta-D Glucan Assay for Diagnosis of Invasive Fungal Infections in Solid Organ Transplant Recipients Beta-D glucan (BDG) assay is a noninvasive test for presumptive diagnosis of invasive fungal infections (IFI). The utility of BDG assay and cut off values for positive, intermediate or negative test has been primarily studied in patients with hematological malignancies. However, the role of BDG in solid organ transplant (SOT) recipients is not well described. The aim of this study is to evaluate the utility of serum BDG assay for IFI diagnosis in SOT recipients.



Isavuconazole Resistance

Achievement of Clinical Isavuconazole (ISA) Serum and Plasma Drug Concentrations in Two Patients with Isavuconazonium Capsules Administered via Nasogastric Feeding Tube (NGT)

Isavuconazole is a broad-spectrum antifungal available in both intravenous (IV) and oral capsule formulations for the treatment of invasive aspergillosis and mucormycosis. Oral administration can be challenging as FDA prescribing information states capsules should not be chewed, crushed, dissolved, or opened. We describe the first two cases, to our knowledge, of patients who received isavuconazonium capsules sprinkled via NGT with concomitant therapeutic drug monitoring (TDM).




Relationship of cumulative viral burden of adenovirus with mortality in allogeneic hematopoietic cell transplant recipients with early adenovirus viremia

Higher peak adenovirus (ADV) viral loads (VL) have correlated with higher mortality in allogeneic hematopoietic cell transplant (HCT) recipients. ADV viral dynamics may inform trial design of new treatment strategies. We examined the relationship between cumulative viral burden expressed as average area under the curve (AAUC) and mortality.



The Best ID Lab for Your Testing Needs


Send your CMV testing to a lab that's leading the industry in CMV testing research and development. For more information on Viracor's CMV test options, please click here

Read how Viracor is taking CMV clinical diagnostic testing to the next level:


New to Viracor?

With over 30 years of specialized expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Viracor is committed to helping medical professionals, transplant teams, reference labs and biopharmaceutical companies get results faster, when it matters most.

We would be honored to be your diagnostic testing partner. For more information and to set up an account, please click on the button below.

Connect with us